Literature DB >> 30239770

Prevalence and Course of Endocrinopathy in POEMS Syndrome.

Francisca Caimari1, Stephen Keddie2,3, Michael P Lunn2,3, Shirley D'Sa4, Stephanie E Baldeweg1.   

Abstract

CONTEXT: POEMS syndrome is a rare multisystem disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, and skin changes, among other features.
OBJECTIVE: To describe the prevalence and course of endocrine dysfunction in POEMS.
DESIGN: Cohort study with systematic review of the endocrinopathy in POEMS.
SETTING: Seventy-five patients with POEMS were evaluated by the multidisciplinary team at our tertiary specialist center. PATIENTS: Endocrine data were available for 59 patients who attended the clinic from June 1999 to May 2018.
INTERVENTIONS: All patients had regular endocrine screening, including testing for diabetes, pituitary and thyroid dysfunction and assessment of bone metabolism. MAIN OUTCOME MEASURE: Prevalence and survival time to develop endocrinopathy in POEMS.
RESULTS: Thirty-four (63%) patients presented with an endocrinopathy at POEMS diagnosis and 54 (92%) had at least one endocrine abnormality at follow-up. The median follow-up was 4.4 (interquartile range, 1.5, 7.9) years. The most common endocrine abnormality was hypogonadism in 68%, followed by hyperprolactinemia (56%), hypothyroidism (54%), abnormal glucose metabolism (24%), adrenal insufficiency (17%), and high IGF-1 levels (15%). Spontaneous resolution of endocrine abnormalities at the end of follow-up was observed: 14% of patients with hypogonadism; 42%, hyperprolactinemia; 34%, hypothyroidism; and 38%, high IGF-1 levels.
CONCLUSIONS: Endocrinopathy was found in 63% of patients at diagnosis and in 92% of patients during follow-up in our cohort. Therefore, patients with POEMS should be systematically assessed for endocrinopathy. The most common deficiencies were hypogonadism and hypothyroidism; however, but endocrinopathy can normalize, so ongoing treatment should remain under review.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30239770     DOI: 10.1210/jc.2018-01516

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Missed diagnosis of POEMS syndrome with onset of progressive fatigue and numbness: a case report.

Authors:  Huan Shi; Xiaohong Jiang; Long Wang; Jiayan Zhou
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

2.  Endocrine Evaluation in POEMS Syndrome: A Cohort Study.

Authors:  Hongbo Yang; Hao Zhao; Xuemin Gao; Xufei Huang; Xinxin Cao; Daobin Zhou; Weibo Xia; Jian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-27       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.